Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin

A. Marosi, L. Dufkova, B. Forró, O. Felde, K. Erdélyi, J. Širmarová, M. Palus, V. Hönig, J. Salát, R. Tikos, M. Gyuranecz, D. Růžek, B. Martina, P. Koraka, ADME. Osterhaus, T. Bakonyi,

. 2019 ; 37 (33) : 4724-4735. [pub] 20180524

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025723
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025723
003      
CZ-PrNML
005      
20230815111822.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2018.05.066 $2 doi
035    __
$a (PubMed)29805091
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Marosi, András $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary. Electronic address: Marosi.Andras@univet.hu.
245    10
$a Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin / $c A. Marosi, L. Dufkova, B. Forró, O. Felde, K. Erdélyi, J. Širmarová, M. Palus, V. Hönig, J. Salát, R. Tikos, M. Gyuranecz, D. Růžek, B. Martina, P. Koraka, ADME. Osterhaus, T. Bakonyi,
520    9_
$a Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.
650    _2
$a zvířata $7 D000818
650    _2
$a protilátky virové $x imunologie $7 D000914
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a imunoglobuliny $x terapeutické užití $7 D007136
650    _2
$a imunohistochemie $7 D007150
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a vzteklina $x farmakoterapie $x imunologie $7 D011818
650    _2
$a virus vztekliny $x účinky léků $x imunologie $x patogenita $7 D011820
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a replikace viru $x účinky léků $7 D014779
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dufkova, Lucie $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
700    1_
$a Forró, Barbara $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
700    1_
$a Felde, Orsolya $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
700    1_
$a Erdélyi, Károly $u National Food Chain Safety Office, Veterinary Diagnostic Directorate, Tábornok u. 2, 1149 Budapest, Hungary.
700    1_
$a Širmarová, Jana $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
700    1_
$a Palus, Martin $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
700    1_
$a Hönig, Václav, $d 1982- $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic. $7 jcu2012681186
700    1_
$a Salát, Jiří $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
700    1_
$a Tikos, Réka $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary.
700    1_
$a Gyuranecz, Miklós $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
700    1_
$a Růžek, Daniel, $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic. $d 1981- $7 stk2008441707
700    1_
$a Martina, Byron $u Artemis One Health Research Foundation, Delft, The Netherlands.
700    1_
$a Koraka, Penelope $u Viroscience Lab, Erasmus Medical Centre, Wytemaweg 80 3015CN, Rotterdam, The Netherlands.
700    1_
$a Osterhaus, Albert D M E $u Artemis One Health Research Foundation, Delft, The Netherlands; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Germany.
700    1_
$a Bakonyi, Tamás $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary; Viral Zoonoses, Emerging and Vector-Borne Infections Group, Institute of Virology, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 37, č. 33 (2019), s. 4724-4735
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29805091 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20230815111819 $b ABA008
999    __
$a ok $b bmc $g 1599868 $s 1116409
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 33 $d 4724-4735 $e 20180524 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...